News & Events

Xenome Limited ("Xenome") today announced that Dr Julie Cherrington has joined the Xenome Board as an independent, Non-Executive Director.

Dr Cherrington is President of Phenomix Corporation, a San Diego based biopharmaceutical company focused on the development and commercialisation of drugs for the treatment of metabolic and infectious diseases. Prior to her appointment as President, Dr Cherrington served as the Executive Vice President of Research and Development at Phenomix. Before joining Phenomix, Dr Cherrrington held senior research positions at prominent biotechnology companies such as SUGEN, Inc. and Gilead Sciences, Inc.

Recently Dr Cherrington joined the Board of ASX and NASDAQ listed Progen Pharmaceuticals Limited. She has also served on the Board of ChemGenex Pharmaceuticals Limited.

Xenome's Chairman, Mr Jim Hazel, welcomed Dr Cherrington's appointment as an important step in the ongoing evolution of the Xenome Board. "We are delighted to have a person of Julie's stature and experience join the Board and look forward to her help in building Xenome as a drug development company."

Dr Cherrington's appointment took effect on 1 August 2009.